32.70 % to Target, Morgan Stanley Reiterates ‘Overweight’ Rating on Clovis Oncology (NASDAQ:CLVS) Shares Today

November 14, 2017 - By Migdalia James

 32.70 % to Target, Morgan Stanley Reiterates ‘Overweight’ Rating on Clovis Oncology (NASDAQ:CLVS) Shares Today

Investors sentiment decreased to 1.81 in 2017 Q2. Its down 0.66, from 2.47 in 2017Q1. It fall, as 33 investors sold Clovis Oncology Inc shares while 56 reduced holdings. 74 funds opened positions while 87 raised stakes. 46.46 million shares or 12.58% more from 41.27 million shares in 2017Q1 were reported.

Morgan Stanley owns 130,409 shares. National Bank & Trust Of Montreal Can has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 2,702 shares. American Group Incorporated, New York-based fund reported 24,416 shares. Sabby Management Limited Liability Company invested in 0.04% or 7,065 shares. First Manhattan Co invested 0.08% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Sg Americas Limited Liability Co has 19,313 shares. 4,000 are owned by Legacy Private Communications. Kazazian Asset Management Limited Liability Corp holds 11,264 shares. Emerald Mutual Fund Advisers owns 205,649 shares or 0.84% of their US portfolio. Barclays Public Ltd Company invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). Us Bank & Trust De accumulated 0% or 94 shares. Pdts Ptnrs Limited Liability Corp owns 19,361 shares or 0.07% of their US portfolio. Tekla Cap Mgmt Limited Liability invested 0.52% in Clovis Oncology Inc (NASDAQ:CLVS). Shell Asset Mngmt accumulated 7,680 shares. Aberdeen Asset Management Public Limited Uk, United Kingdom-based fund reported 5,863 shares.

Since May 15, 2017, it had 0 buys, and 1 insider sale for $185,460 activity.

Clovis Oncology (NASDAQ:CLVS) Rating Reaffirmed

In a report published on Thursday, 2 November, The Overweight rating of Clovis Oncology (NASDAQ:CLVS) shares was maintained by Analysts at Morgan Stanley, who now has a $86 target price per share on the stock. Morgan Stanley’s target price per share means a possible upside of 32.70 % from the stock close price of the company.

Investors sentiment decreased to 1.81 in 2017 Q2. Its down 0.66, from 2.47 in 2017Q1. It fall, as 33 investors sold Clovis Oncology Inc shares while 56 reduced holdings. 74 funds opened positions while 87 raised stakes. 46.46 million shares or 12.58% more from 41.27 million shares in 2017Q1 were reported.

Morgan Stanley owns 130,409 shares. National Bank & Trust Of Montreal Can has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 2,702 shares. American Group Incorporated, New York-based fund reported 24,416 shares. Sabby Management Limited Liability Company invested in 0.04% or 7,065 shares. First Manhattan Co invested 0.08% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). Sg Americas Limited Liability Co has 19,313 shares. 4,000 are owned by Legacy Private Communications. Kazazian Asset Management Limited Liability Corp holds 11,264 shares. Emerald Mutual Fund Advisers owns 205,649 shares or 0.84% of their US portfolio. Barclays Public Ltd Company invested 0.01% in Clovis Oncology Inc (NASDAQ:CLVS). Us Bank & Trust De accumulated 0% or 94 shares. Pdts Ptnrs Limited Liability Corp owns 19,361 shares or 0.07% of their US portfolio. Tekla Cap Mgmt Limited Liability invested 0.52% in Clovis Oncology Inc (NASDAQ:CLVS). Shell Asset Mngmt accumulated 7,680 shares. Aberdeen Asset Management Public Limited Uk, United Kingdom-based fund reported 5,863 shares.

Since May 15, 2017, it had 0 buys, and 1 insider sale for $185,460 activity.

Clovis Oncology Inc (NASDAQ:CLVS) Ratings Coverage

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology has $134 highest and $15 lowest target. $73.22’s average target is 12.98% above currents $64.81 stock price. Clovis Oncology had 53 analyst reports since September 10, 2015 according to SRatingsIntel. The rating was upgraded by Chardan Capital Markets on Monday, June 19 to “Neutral”. J.P. Morgan maintained Clovis Oncology Inc (NASDAQ:CLVS) on Wednesday, September 6 with “Buy” rating. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The stock has “Buy” rating by J.P. Morgan on Thursday, June 1. As per Monday, November 16, the company rating was downgraded by Mizuho. On Tuesday, December 20 the stock rating was upgraded by Chardan Capital Markets to “Neutral”. Stifel Nicolaus maintained it with “Buy” rating and $45 target in Wednesday, September 21 report. On Monday, January 23 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm has “Buy” rating given on Monday, September 11 by Stifel Nicolaus. Credit Suisse maintained Clovis Oncology Inc (NASDAQ:CLVS) rating on Tuesday, July 18. Credit Suisse has “Buy” rating and $10700 target.

About 1.07 million shares traded. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since November 14, 2016 and is uptrending. It has outperformed by 266.01% the S&P500.

Analysts await Clovis Oncology Inc (NASDAQ:CLVS) to report earnings on February, 28. They expect $-1.27 EPS, up 30.60 % or $0.56 from last year’s $-1.83 per share. After $-1.24 actual EPS reported by Clovis Oncology Inc for the previous quarter, Wall Street now forecasts 2.42 % negative EPS growth.

Clovis Oncology, Inc. is a biopharmaceutical firm focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The company has market cap of $3.21 billion. The Company’s product candidates include Rociletinib, Rubraca and Lucitanib. It currently has negative earnings. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

More important recent Clovis Oncology Inc (NASDAQ:CLVS) news were published by: Gurufocus.com which released: “Columbia Wanger Buys Loxo Oncology Inc, Clovis Oncology Inc, Cognex Corp …” on November 13, 2017, also Bizwest.com published article titled: “Clovis Oncology misses on earnings, revenue”, Businesswire.com published: “Clovis Oncology to Present at the Stifel 2017 Healthcare Conference” on November 08, 2017. More interesting news about Clovis Oncology Inc (NASDAQ:CLVS) was released by: Businesswire.com and their article: “Clovis Oncology Announces Third Quarter 2017 Operating Results” with publication date: November 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: